Real-World Epidemiology of Potassium Derangements Among Chronic Cardiovascular, Metabolic and Renal Conditions: A Population-Based Analysis

References

• Rosano GMC, Tamargo J, Kjeldsen KP, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the working group on cardiovascular pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother. 2018;4:180–188. doi:10.1093/ehjcvp/pvy01529726985
   PubMed Web of Science ®Google Scholar
• Collins AJ, Pitt B, Reaven N, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol. 2017;46:213–221. doi:10.1159/00047980228866674
   PubMed Web of Science ®Google Scholar
• De Nicola L, Di Lullo L, Paoletti E, Cupisti A, Bianchi S. Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice. J Nephrol. 2018;31(5):653–664. doi:10.1007/s40620-018-0502-629882199
   PubMed Web of Science ®Google Scholar
• Sarwar CM, Papadimitriou L, Pitt B, et al. Hyperkalemia in heart failure. J Am Coll Cardiol. 2016;68:1575–1589. doi:10.1016/j.jacc.2016.06.06027687200
   PubMed Web of Science ®Google Scholar
• Bandak G, Sang Y, Gasparini A, et al. Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatininemeasurements (SCREAM) project. J Am Heart Assoc. 2017;6:e005428. doi:10.1161/JAHA.116.00542828724651
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200. doi:10.1093/eurheartj/ehw12827206819
   PubMed Web of Science ®Google Scholar
• Yancy CW, Januzzi JL Jr, Allen LA, et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology task force on expert consensus decision pathways. J Am Coll Cardiol. 2018;71:201–230. doi:10.1016/j.jacc.2017.11.02529277252
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2017b;138:e426–e483.
   Web of Science ®Google Scholar
• Cooper LB, Hammill BG, Peterson ED, et al. Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. JAMA. 2015;314:1973–1975. doi:10.1001/jama.2015.1190426547470
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Matsushita K, Sang Y, et al.; CKD Prognosis Consortium. Serum potassium and adverse outcomes across the range of kidney function: a Ckd prognosisconsortium meta-analysis. Eur Heart J. 2018;39:1535–1542. doi:10.1093/eurheartj/ehy10029554312
   PubMed Web of Science ®Google Scholar
• Beusekamp JC, Tromp J, van der Wal HH, et al. Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. Eur J Heart Fail. 2018;20:923–930. doi:10.1002/ejhf.107929327797
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869. doi:10.1056/NEJMoa01116111565518
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation Study Investigators. N Engl J Med. 1999;341(10):709–717. doi:10.1056/NEJM19990902341100110471456
   PubMed Web of Science ®Google Scholar
• Eschalier R, McMurray JJ, Swedberg K, et al.; EMPHASIS-HF Investigators. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol. 2013;62:1585–1593. doi:10.1016/j.jacc.2013.04.08623810881
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al.; PARADIGM-HF Investigators And Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. doi:10.1056/NEJMoa140907725176015
   PubMed Web of Science ®Google Scholar
• Hughes-Austin JM, Rifkin DE, Beben T, et al. The relation of serum potassium concentration with cardiovascular events and mortality in community-living individuals. Clin J Am Soc Nephrol. 2017;12(2):245–252. doi:10.2215/CJN.0629061628143865
   PubMed Web of Science ®Google Scholar
• Jain N, Kotla S, Little BB, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol. 2012;109:1510–1513. doi:10.1016/j.amjcard.2012.01.36722342847
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Blacklock R, Wood E, et al. Prevalence And Factors Associated With Hyperkalemia In Predialysis Patients Followed In A Low-Clearance Clinic. Clin J Am Soc Nephrol. 2012;7:1234–1241. doi:10.2215/CJN.0115011222595825
   PubMed Web of Science ®Google Scholar
• Thomsen RW, Nicolaisen SK, Hasvold P, et al. Elevated potassium levels in patients with congestive heart failure: occurrence, risk factors, and clinical outcomes: a Danish Population-Based Cohort Study. J Am Heart Assoc. 2018;7. doi:10.1161/JAHA.118.008912
   Web of Science ®Google Scholar
• Crespo-Leiro MG, Barge-Caballero E, Segovia-Cubero J, et al. Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA heart failure long-term registry. Rev Esp Cardiol. 2019;S1885-5857(19)30285–3.
   Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al.; ESC Scientific Document Group. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–3104.30165516
   PubMed Web of Science ®Google Scholar
• Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int. 2017;92(1):26–36. doi:10.1016/j.kint.2017.04.00628646995
   PubMed Web of Science ®Google Scholar
• Núñez J, Bayés-Genís A, Zannad F, et al. Long-term potassium monitoring and dynamics in heart failure and risk of mortality. Circulation. 2018;27(137):1320–1330. doi:10.1161/CIRCULATIONAHA.117.030576
   Web of Science ®Google Scholar
• Verdu JM, Comın-Colet J, Domingo M, et al. Rapid point-of-care NT-proBNP optimal cut-off point for heart failure diagnosis in primary care. Rev Esp Cardiol. 2012;65:613–619. doi:10.1016/j.recesp.2012.01.01922541282
   PubMed Web of Science ®Google Scholar